RxSight stock tumbles on reduced 2026 sales guidance

RxSight shares fell 12.9% after the company cut 2026 sales guidance to $110–$120M (from $120–$135M) citing “meaningful commercial headwinds” in the intraocular lens market. Q2 2026 preliminary total revenue is guided at $32–$34M, including $5–$7M from a strategic Alcon collaboration and ~$27M in product sales, alongside more widespread competitive trialing. RxSight offset some pressure with higher gross margin guidance of 73%–75% and plans to accelerate sales force/commercial investments while keeping operating expenses at the high end of $150–$160M.

Analysis

The key issue is not the near-term revenue reset itself, but the signal that this market is moving from a product-story to a distribution-war. Once surgeons start broadly trialing alternatives, switching costs tend to drop faster than management teams expect, and the winner is usually the incumbent with the deepest commercial footprint rather than the best clinical slide deck. That argues for persistent share pressure on RXST over the next 1-3 quarters, even if gross margin holds up temporarily.

The margin improvement is the part the market may overread. Higher gross margin does little if the company must spend more on sales coverage just to defend install base and conversion rates; in other words, the operating leverage is now more fragile, not less. The cash balance buys time, but it also gives the company room to spend into a share war, which can delay but not solve the underlying demand-quality problem.

ALC is the cleaner relative winner because it can absorb share via broader surgeon relationships and a more diversified commercial engine. The collaboration revenue is not large enough to move the needle by itself, but it validates that the strategic value is in distribution and ecosystem access, not just product differentiation. Over 6-18 months, the risk for RXST is multiple compression if the market decides this is a slower adoption curve, while ALC should be more insulated unless the competitive intensity starts hurting its own premium IOL economics.

Contrarian take: the move may still be underdone if investors are focused on the revenue guide cut and ignoring the commercial-language change from execution issue to competitive issue. The thesis breaks only if next quarter shows stabilization in unit sales, evidence that trialing is converting back into placements, or if new products materially shorten workflow friction enough to re-accelerate adoption.

Key Decisions for Investors

• Short RXST on rallies or via 1-3 month put spreads; the risk/reward is attractive if the market begins to price in a longer share-loss cycle rather than a one-quarter stumble. Falsifier: sequential unit placements stabilize and management stops leaning on incremental sales spending.
• Pair trade: long ALC / short RXST for 1-3 months to express relative commercial strength in ophthalmology. ALC is the cleaner beneficiary if trialing remains elevated and channel relationships matter more than product novelty.
• If option liquidity is workable, buy RXST puts into any post-guidance bounce; this is a name where the second leg of the downgrade often comes from margin/opex revisions, not just revenue. Stop if the company raises placement guidance or demonstrates accelerating conversion.
• Watch ALC only as an alert, not a high-conviction long: upside depends on whether its collaboration proves strategically sticky beyond a modest revenue contribution. If RXST re-accelerates or ALC commentary implies no share capture, close the pair.